News

Enlarge image

BusinessFrance

Baxter buys OBI-1 assets

22.03.2013 - French Ipsen and its insolvent partner Inspiration Biopharmaceuticals Inc announced the closing of the sale of OBI-1 to Baxter International Inc.

The transaction, which strengthens Baxter as global leader in haemophilia, was announced at the end of January. Under the terms of the agreement, Ipsen and Inspiration will sell their rights on OBI-1 together with Ipsen's manufacturing plant in Millford. Recombinant porcine factor VIII under development for the treatment of congenital hemophilia A with inhibitors and acquired haemophilia A, as well as Ipsen's manufacturing facility for OBI-1 in Milford, Massachusetts are in the deal. The Ipsen employees working on the development and manufacturing of OBI-1 will be offered employment by Baxter.   Baxter will pay US$50m upfront, and up to US$135m in milestones as well as net sales payments up to 17.5%. The recombinant porcine factor VIII is currently in a pivotal trial for the treatment of individuals with acquired haemophilia A.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/baxter-buys-obi-1-assets.html

R&DUKIreland

12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PAION (D)1.77 EUR63.89%
  • 4SC (D)2.95 EUR11.32%
  • BIONOR PHARMA (N)0.86 NOK8.86%

FLOP

  • STENTYS (F)2.83 EUR-26.30%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • KARO BIO (S)24.60 SEK-16.04%

TOP

  • VERONA PHARMA (UK)3.40 GBP25.9%
  • IXICO (UK)35.75 GBP21.2%
  • SERODUS (N)2.71 NOK15.8%

FLOP

  • BIONOR PHARMA (N)0.86 NOK-47.2%
  • STENTYS (F)2.83 EUR-44.3%
  • MOLMED (I)0.24 EUR-35.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.60 SEK3053.8%
  • 4SC (D)2.95 EUR243.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-86.0%
  • BIOTEST (D)13.79 EUR-85.3%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 13.02.2016